George Brooks - Teladoc CoFounder
| 4LL Stock | EUR 9.02 0.34 3.92% |
Insider
George Brooks is CoFounder of Teladoc
| Phone | 203 635 2002 |
| Web | https://www.teladochealth.com |
Teladoc Management Efficiency
The company has return on total asset (ROA) of (0.0129) % which means that it has lost $0.0129 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4885) %, meaning that it generated substantial loss on money invested by shareholders. Teladoc's management efficiency ratios could be used to measure how well Teladoc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Steve Lindsay | Healthequity | N/A | |
| Jun Wu | Ping An Healthcare | 57 | |
| Dan McCarthy | Evolent Health | N/A | |
| Eleni Zuppas | Veeva Systems | 53 | |
| Tyson Murdock | Healthequity | 52 | |
| Emanuele Mugnani | Compugroup Medical SE | 53 | |
| Bryan Roberts | 10X GENOMICS DL | 52 | |
| Elimelech Rosner | Healthequity | 66 | |
| Alexander Weimer | Compugroup Medical SE | N/A | |
| Jacques Mourrain | Veeva Systems | N/A | |
| Brad Bennion | Healthequity | N/A | |
| Luoqi Zang | Ping An Healthcare | 42 | |
| Eckart Pech | Compugroup Medical SE | 54 | |
| Benjamin Hindson | 10X GENOMICS DL | 44 | |
| Oliver Bruzek | Compugroup Medical SE | N/A | |
| Jean Philibert | 10X GENOMICS DL | 59 | |
| Mathai Mammen | 10X GENOMICS DL | 51 | |
| Jonathan JD | Evolent Health | 55 | |
| Kali Beyah | Evolent Health | N/A | |
| Tia Padia | Healthequity | N/A | |
| Brad Crutchfield | 10X GENOMICS DL | N/A | |
Management Performance
| Return On Equity | -1.49 | |||
| Return On Asset | -0.0129 |
Teladoc Leadership Team
Elected by the shareholders, the Teladoc's board of directors comprises two types of representatives: Teladoc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teladoc. The board's role is to monitor Teladoc's management team and ensure that shareholders' interests are well served. Teladoc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teladoc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Goldstein, Independent Director | ||
| Mike Waters, Chief Officer | ||
| Andrew Turitz, Senior Vice President of Business Development | ||
| Catherine Jacobson, Independent Director | ||
| Sandra Fenwick, Director | ||
| Michelle Bucaria, Chief Human Resource Officer | ||
| Christopher Bischoff, Director | ||
| David Shedlarz, Independent Director | ||
| William Frist, Independent Director | ||
| Mala Murthy, Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Controller | ||
| Mark Smith, Independent Director | ||
| David Snow, Independent Chairman of the Board | ||
| David Sides, Chief Operating Officer | ||
| Richard Napolitano, Chief VP | ||
| Thomas McKinley, Independent Director | ||
| Christopher Caridi, Senior Vice President Chief Accounting Officer, Controller | ||
| Karen Daniel, Director | ||
| Lewis Levy, Chief Medical Officer | ||
| Claus Jensen, Chief Officer | ||
| Adam Vandervoort, Chief Legal Officer and Secretary | ||
| Gabriel Cappucci, Senior Vice President Chief Accounting Officer, Controller | ||
| Kenneth Paulus, Independent Director | ||
| Stephanie Verstraete, Chief Marketing Officer | ||
| George Brooks, CoFounder | ||
| Hemant Taneja, Director | ||
| Glen Tullman, Director | ||
| Helen Darling, Independent Director | ||
| CPA CFA, VP Relations | ||
| Jason Gorevic, Chief Executive Officer, Director | ||
| Courtney McLeod, Director Communication |
Teladoc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teladoc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.49 | |||
| Return On Asset | -0.0129 | |||
| Operating Margin | (0.09) % | |||
| Current Valuation | 5.01 B | |||
| Shares Outstanding | 162.84 M | |||
| Shares Owned By Insiders | 0.96 % | |||
| Shares Owned By Institutions | 82.07 % | |||
| Price To Book | 0.75 X | |||
| Price To Sales | 1.77 X | |||
| Revenue | 2.41 B |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Teladoc Stock
When determining whether Teladoc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teladoc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teladoc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teladoc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Teladoc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Teladoc Stock please use our How to Invest in Teladoc guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.